Traders should view this acquisition as a strategic pipeline enhancement in a high-growth therapeutic area. The addition of HS235 strengthens GSK's position in pulmonary hypertension and could yield near-term clinical catalysts from upcoming proof-of-concept trials. Monitor for Phase 2 data readouts in PAH and PH-HFpEF as key value inflection points.
Price Chart
Executive Summary
GSK plc has completed its acquisition of 35Pharma Inc., a clinical-stage biopharmaceutical company, for $950 million. The deal brings HS235, a potential best-in-class therapy for pulmonary hypertension (PH), into GSK's pipeline, targeting the activin receptor pathway with potential metabolic benefits.
Key Facts
- GSK completed the acquisition of 35Pharma Inc. for $950 million.
- The acquisition includes HS235, a novel protein-based therapeutic for pulmonary hypertension (PH).
- HS235 targets the activin receptor signalling pathway and is designed to reduce risks of bleeding and pericardial effusion compared to current PAH treatments.
- HS235 may offer metabolic benefits such as fat-selective weight loss and improved insulin sensitivity, potentially expanding its clinical utility.
- Proof-of-concept trials for HS235 are expected to begin soon in PAH and PH-HFpEF indications.
- The global PH therapy market is projected to reach $18 billion by 2032, with activin inhibitors expected to capture 50% of that market.
Financial Impact
GSK paid $950 million in equity consideration to acquire 100% of 35Pharma Inc., representing a significant but non-dilutive investment in its respiratory and inflammation pipeline.
Risk Factors
- HS235 is still in clinical development; future trial results may not confirm early efficacy or safety advantages.
- Forward-looking statements are subject to risks outlined in GSK's 20-F, including regulatory, development, and commercialization risks.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003518 |
| Document: 0001654954-26-003518-index-headers.html | 0001654954-26-003518 |
| Document: 0001654954-26-003518-index.html | 0001654954-26-003518 |
| Document: 0001654954-26-003518.txt | 0001654954-26-003518 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $25.12 $25.25 | ▲ +0.52% | ▼ −1.62% | $26.12 (+3.98%) |
Jun 9, 2026 19w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 9, 2026 20w ago | 6-K | $24.66 $25.50 | ▲ +3.41% | ▲ +1.60% | $26.12 (+5.92%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
Jun 1, 2026 21w ago | 6-K | $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $26.12 (+7.71%) |
May 28, 2026 21w ago | 6-K | $24.58 $24.66 | ▲ +0.33% | ▲ +0.01% | $26.12 (+6.27%) |
May 27, 2026 21w ago | 6-K | $25.57 $23.94 | ▼ −6.37% | ▼ −7.58% | $26.12 (+2.15%) |
May 26, 2026 21w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 26, 2026 21w ago | 6-K | $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $26.12 (+2.43%) |
May 22, 2026 22w ago | 6-K | $26.00 $24.25 | ▼ −6.73% | ▼ −8.39% | $26.12 (+0.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers